Currently, two CAR-T cell approaches (Figure 3) targeting the folate receptor alpha (FRα) and the prostate-specific membrane antigen (PSMA) are in phase I/II studies for bladder cancer (NCT03185468). This evidence concerns the gene FOLH1 and urinary bladder cancer.